Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-1015 in Resistant/Refractory Epithelial Ovarian Cancer
NCT05617755Phase 1Terminated
- Sponsor
- Arsenal Biosciences, Inc.
- Start
- Nov 2022
- Primary completion
- Sep 2024
- Modality
- Gene Silencing, CRISPR-Cas9, Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AB-1015 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Arsenal Biosciences, Inc. Primary endpoints: Incidence of adverse events and dose limiting toxicities at 2 years and Maximal tolerated dose at 21 days. Started Nov 2022; status: terminated.
02
Drugs
AB-1015
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05617755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05617755.